Immuneering Corporation
IMRX
$1.64
$0.085.13%
Headlines
5/1/2024
-
Zolmax
4/17/2024
-
Zolmax
4/16/2024
-
Zolmax
4/14/2024
-
Ticker Report
4/14/2024
-
Zolmax
4/12/2024
-
TipRanks Financial Blog
4/12/2024
-
TipRanks Financial Blog
4/9/2024
-
The Fly
4/9/2024
-
Globe Newswire
4/5/2024
-
Ticker Report
4/3/2024
-
Globe Newswire
4/2/2024
-
The Fly
3/29/2024
-
TipRanks Financial Blog
3/27/2024
-
The Fly
3/27/2024
-
Globe Newswire
3/25/2024
-
Ticker Report
3/25/2024
-
Ticker Report
3/22/2024
-
Ticker Report
3/22/2024
-
Ticker Report
3/22/2024
-
Ticker Report
3/22/2024
-
Zolmax
3/21/2024
-
Simply Wall St
3/20/2024
-
GuruFocus
Filings
Friday, March 1, 2024
Sunday, December 31, 2023
Beginning of May (est)
Price History
--
--
Business Description
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a...
more